查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1589657

湿疹治疗药物市场：按治疗方法、分销管道划分 - 全球预测 2025-2030 年

Eczema Therapeutics Market by Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors), Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年湿疹治疗药物市场规模为68.6亿美元，预计2024年将达到74.9亿美元，复合年增长率为9.59%，预计到2030年将达到130.2亿美元。

全球湿疹治疗药物市场的重点是治疗湿疹的药物的开发和供应，湿疹是一种以瘙痒和发炎为特征的慢性发炎皮肤病。该市场包括处方药、非处方生物製药和旨在控制症状和改善患者生活品质的替代疗法。湿疹的盛行率不断上升，尤其是在儿童中，其慢性状态以及人们对皮肤健康意识的不断增强推动了对湿疹治疗的需求。这些治疗方法主要应用于医院和诊所等医疗机构，但随着配方和输送系统的改进，正在扩展到居家照护。最终用途范围扩展到寻求症状缓解的个人和提供全面治疗计划的皮肤科医生。

主要市场统计
基准年[2023] 68.6亿美元
预测年份 [2024] 74.9亿美元
预测年份 [2030] 130.2亿美元
复合年增长率（%） 9.59%

关键的市场成长要素包括医学研究的进步导致新型生物治疗、局部治疗组合的扩大以及皮肤病学研究和开发投资的增加。开发个人化医疗方法和利用数位工具进行远端监测和远距皮肤科咨询也有机会。为了利用这些机会，我们建议与高科技公司和医疗保健平台建立伙伴关係，并采取创新措施来提高患者的参与度和治疗依从性。

该市场面临的挑战包括先进生技药品的高价格、严格的法规环境以及长期药物的潜在副作用。此外，来自学名药和替代疗法的竞争也是一个主要障碍。如果没有对产品差异化的策略重点，这些限制可能会阻碍市场成长。

需要技术创新的领域包括探索微针贴片和经皮製剂等新型给药系统，以及追求环保和永续的製剂。透过投资了解微生物组对湿疹的影响并整合人工智慧驱动的资料分析以提高治疗效果，公司可以大大受益。

市场格局是动态的，快速发展塑造了治疗格局和消费者偏好。因此，需要持续研究和适应新的科学考量和技术发展，以保持竞争优势并推动业务成长。

市场动态：揭示快速发展的湿疹治疗药物市场的关键市场洞察

湿疹治疗市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 皮肤粗糙、湿疹等皮肤相关疾病的发生
    • 政府措施和宣传宣传活动对预防湿疹的正面影响
    • 扩大报销政策的适用范围
  • 市场限制因素
    • 与未治疗的疾病和皮质类固醇的副作用相关的问题
  • 市场机会
    • 治疗药物的监管核准增加
    • 新湿疹治疗的进展和产品发布
  • 市场挑战
    • 非专利治疗和产品召回简介

波特五力：开拓湿疹药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解湿疹治疗市场的外部影响

外部宏观环境因素在塑造湿疹治疗药物市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解湿疹治疗药物市场的竞争状况

对湿疹治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵湿疹治疗市场供应商绩效评估

FPNV定位矩阵是评估湿疹治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘湿疹治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对湿疹治疗药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 皮肤发炎、湿疹和其他皮肤相关疾病的发生率
      • 政府优先采取的湿疹预防措施和宣传活动
      • 扩大退款政策的适用范围
    • 抑制因素
      • 不治之症和类固醇副作用的问题
    • 机会
      • 治疗药物的监管核准增加
      • 新湿疹治疗的新进展和产品发布
    • 任务
      • 学名药和产品召回简介
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗分类的湿疹治疗药物市场

  • 抗生素
  • 抗组织胺药
  • Calcineurin抑制剂
  • 皮质类固醇
  • 润肤剂和保湿剂
  • 免疫调节剂
  • 白细胞介素抑制剂

第七章湿疹治疗药物市场：依通路

  • 医院/诊所
  • 网路药房
  • 零售药房

第八章北美和南美湿疹治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太湿疹治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第10章欧洲、中东和非洲的湿疹治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie, Inc.
  • Alliance Pharma PLC
  • Amneal Pharmaceuticals LLC
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Cadila Pharmaceuticals Limited
  • Eli Lilly and Company
  • Encore Dermatology Inc.
  • F. Hoffmann-La Roche Ltd.
  • Glenmark Pharmaceuticals Limited
  • GSK PLC
  • Incyte Corporation
  • Novartis AG
  • Pfizer Inc.
Product Code: MRR-2D668742E87B

The Eczema Therapeutics Market was valued at USD 6.86 billion in 2023, expected to reach USD 7.49 billion in 2024, and is projected to grow at a CAGR of 9.59%, to USD 13.02 billion by 2030.

The global eczema therapeutics market focuses on developing and supplying treatments for eczema, a chronic inflammatory skin condition characterized by itchy and inflamed skin. This market includes prescription medications, over-the-counter treatments, biologics, and alternative therapies aimed at managing symptoms and improving patient quality of life. The necessity for eczema therapeutics is driven by increasing prevalence, especially among children, the chronic nature of the disease, and rising awareness about skin health. These treatments are primarily applied in healthcare settings like hospitals and clinics, but they are also expanding into home care due to improved formulations and delivery systems. End-use scope extends to individuals seeking symptom relief and dermatologists providing comprehensive treatment plans.

KEY MARKET STATISTICS
Base Year [2023] USD 6.86 billion
Estimated Year [2024] USD 7.49 billion
Forecast Year [2030] USD 13.02 billion
CAGR (%) 9.59%

Key market growth factors include advancements in medical research leading to novel biologic therapies, an expanding portfolio of topical treatments, and increased investment in dermatological R&D. Opportunities lie in developing personalized medicine approaches and leveraging digital tools for remote monitoring and teledermatology consultations. A recommendation to harness these opportunities involves fostering partnerships with tech companies and healthcare platforms to innovate and improve patient engagement and adherence to treatment regimens.

Challenges in this market are evident in the high cost of advanced biologics, stringent regulatory environments, and potential side effects of long-term medication use. Additionally, competition from generic products and alternative therapies poses significant hurdles. Market growth could be hindered by these limitations without strategic focus on differentiating product offerings.

Areas ripe for innovation include the exploration of new drug delivery systems, such as microneedle patches and transdermal applications, as well as pursuing eco-friendly and sustainable formulations. Businesses could greatly benefit from investing in understanding microbiome impacts on eczema and integrating AI-driven data analysis to enhance treatment efficacy.

The nature of the eczema therapeutics market is dynamic, with rapid advancements shaping treatment landscapes and consumer preferences. This necessitates ongoing research and adaptation to new scientific insights and technological developments to maintain competitive advantages and foster business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Eczema Therapeutics Market

The Eczema Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Incidences of skin irritation, eczema, and other skin related conditions
    • Favorable government initiatives and awareness campaigns to prevent eczema
    • Growing availability of reimbursement policies
  • Market Restraints
    • Issues regarding non-curable diseases and adverse side effects from corticosteroids
  • Market Opportunities
    • Increasing approvals for therapeutics from the regulatory authorities
    • New advancements and product launches of new eczema therapeutics
  • Market Challenges
    • Introduction of generic treatments and product recalls

Porter's Five Forces: A Strategic Tool for Navigating the Eczema Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Eczema Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Eczema Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Eczema Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Eczema Therapeutics Market

A detailed market share analysis in the Eczema Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Eczema Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Eczema Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Eczema Therapeutics Market

A strategic analysis of the Eczema Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Eczema Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Alliance Pharma PLC, Amneal Pharmaceuticals LLC, Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Cadila Pharmaceuticals Limited, Eli Lilly and Company, Encore Dermatology Inc., F. Hoffmann-La Roche Ltd., Glenmark Pharmaceuticals Limited, GSK PLC, Incyte Corporation, Novartis AG, and Pfizer Inc..

Market Segmentation & Coverage

This research report categorizes the Eczema Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, and Interleukin Inhibitors.
  • Based on Distribution Channel, market is studied across Hospital & Clinics, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Incidences of skin irritation, eczema, and other skin related conditions
      • 5.1.1.2. Favorable government initiatives and awareness campaigns to prevent eczema
      • 5.1.1.3. Growing availability of reimbursement policies
    • 5.1.2. Restraints
      • 5.1.2.1. Issues regarding non-curable diseases and adverse side effects from corticosteroids
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing approvals for therapeutics from the regulatory authorities
      • 5.1.3.2. New advancements and product launches of new eczema therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Introduction of generic treatments and product recalls
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Eczema Therapeutics Market, by Treatment

  • 6.1. Introduction
  • 6.2. Antibiotics
  • 6.3. Antihistamines
  • 6.4. Calcineurin Inhibitors
  • 6.5. Corticosteroids
  • 6.6. Emollients & Moisturizers
  • 6.7. Immunomodulators
  • 6.8. Interleukin Inhibitors

7. Eczema Therapeutics Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital & Clinics
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies

8. Americas Eczema Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Eczema Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Eczema Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie, Inc.
  • 2. Alliance Pharma PLC
  • 3. Amneal Pharmaceuticals LLC
  • 4. Astellas Pharma Inc.
  • 5. AstraZeneca PLC
  • 6. Bausch Health Companies Inc.
  • 7. Bayer AG
  • 8. Cadila Pharmaceuticals Limited
  • 9. Eli Lilly and Company
  • 10. Encore Dermatology Inc.
  • 11. F. Hoffmann-La Roche Ltd.
  • 12. Glenmark Pharmaceuticals Limited
  • 13. GSK PLC
  • 14. Incyte Corporation
  • 15. Novartis AG
  • 16. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. ECZEMA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ECZEMA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ECZEMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ECZEMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ECZEMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ECZEMA THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY EMOLLIENTS & MOISTURIZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. AUSTRALIA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. AUSTRALIA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. CHINA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. CHINA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. INDIA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. INDIA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. INDONESIA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. INDONESIA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. JAPAN ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. JAPAN ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. MALAYSIA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. MALAYSIA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. PHILIPPINES ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. PHILIPPINES ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. SINGAPORE ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. SINGAPORE ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. SOUTH KOREA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. SOUTH KOREA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. TAIWAN ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. TAIWAN ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. THAILAND ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. THAILAND ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. VIETNAM ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. VIETNAM ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. DENMARK ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. DENMARK ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. EGYPT ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. EGYPT ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. FINLAND ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. FINLAND ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. FRANCE ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. FRANCE ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. GERMANY ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. GERMANY ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. ISRAEL ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. ISRAEL ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. ITALY ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. ITALY ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. NETHERLANDS ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. NETHERLANDS ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. NIGERIA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. NIGERIA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. NORWAY ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. NORWAY ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. POLAND ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. POLAND ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. QATAR ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. QATAR ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. RUSSIA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. RUSSIA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SAUDI ARABIA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. SAUDI ARABIA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. SPAIN ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. SPAIN ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. SWEDEN ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. SWEDEN ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. SWITZERLAND ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. SWITZERLAND ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. TURKEY ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. TURKEY ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED ARAB EMIRATES ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED ARAB EMIRATES ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED KINGDOM ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED KINGDOM ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. ECZEMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 106. ECZEMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023